{'fraction_non_alphanumeric': 0.01977401129943503, 'fraction_numerical': 0.005649717514124294, 'mean_word_length': 5.219298245614035, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Ribavirin: a role in HIV infection?

A certain degree of controversy has surrounded the multicenter dose comparison clinical trial of oral ribavirin for patients with HIV-related lymphadenopathy since its inception in 1987. The Journal of Acquired Immune Deficiency Syndromes presented in this issue the peer-reviewed data as it was collected, analyzed, and summarized by a team of researchers headed by Richard B. Roberts, Vice Chairman and Professor of the Department of Medicine, Cornell University Medical College, New York, NY. Herewith is presented an invited Editorial Commentary in response to those clinicians who suggested that an opposing point of view should be heard in the interest of fairness.